Tag: HbA1c

NICE recommendation for Steglatro in type II diabetes

by Anna Smith | Mar 27, 2019 | News | 0

MSD’s SGLT-2 inhibitor Steglatro will be available for some patients with type II diabetes on the NHS in England and Wales.

EU approves AZ’ Bydureon BCise device

by Selina McKee | Aug 30, 2018 | News | 0

AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon.

Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction

by Selina McKee | Jun 29, 2018 | News | 0

Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.

GP referrals to Weight Watchers cut diabetes risk

by Selina McKee | Oct 18, 2017 | News | 0

More than one third of patients referred by GPs to Weight Watchers in a bid to stave off diabetes saw their blood sugar levels return to normal, a study published in the British Medical Journal has found.